For example, analysis of the metastatic colorectal cancer xenopatients cohort allowed to identify HER2 as a predictor of resistance to anti-EGFR antibodies and as a predictor of response to combinatorial therapies against HER2 and EGFR in this tumor setting [72]. This evidence concerns the gene ERBB2 and neoplasm.